Analytical Data
-
Gene name
PSP94/MSMB
- Application
-
Alternative Names
MSM-B; IGBF; MSP; MSPB; PN44; PRPS; PSP; PSP57; PSP94; Immunoglobulin-binding factor; Prostate secreted seminal plasma protein; plasma beta-inhibin
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O08540
-
Expression Region
Val21~Met113
-
Molecular Weight
41kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The PSP94/MSMB protein, also known as Prostate Secretory Protein of 94 amino acids (PSP94) and Microseminoprotein-beta (MSMB), has garnered significant attention in recent years due to its potential roles in prostate health and disease. Initially identified as a secretory protein in the prostate, PSP94 has been implicated in various physiological processes, including the regulation of prostate epithelial cell function and inflammatory responses. Research has shown that altered expression levels of PSP94/MSMB are associated with prostate cancer progression, making it a candidate for biomarkers in early detection and prognosis. Moreover, studies have suggested that PSP94 may possess anti-inflammatory and anti-tumor properties, providing a potential therapeutic target for prostate cancer treatment. Investigating the structure, function, and molecular pathways of PSP94/MSMB can enhance our understanding of its biological roles and therapeutic potential, paving the way for novel diagnostic and treatment strategies in urology. Therefore, the study of this recombinant protein is crucial for elucidating its contributions to prostate health and the underlying mechanisms of prostate malignancies.
